Evogene Ltd. (EVGN)

NASDAQ: EVGN · IEX Real-Time Price · USD
0.760
+0.005 (0.66%)
At close: Oct 4, 2022 4:00 PM
0.799
+0.039 (5.09%)
After-hours: Oct 4, 2022 7:18 PM EDT
0.66%
Market Cap 35.16M
Revenue (ttm) 1.01M
Net Income (ttm) -32.08M
Shares Out 46.28M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,337
Open 0.796
Previous Close 0.755
Day's Range 0.750 - 0.806
52-Week Range 0.680 - 2.930
Beta 0.98
Analysts Buy
Price Target 6.63 (+772.6%)
Earnings Date Aug 31, 2022

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and... [Read more...]

Industry Biotechnology
Founded 1999
Employees 133
Stock Exchange NASDAQ
Ticker Symbol EVGN
Full Company Profile

Financial Performance

In 2021, Evogene's revenue was $930,000, a decrease of -10.58% compared to the previous year's $1.04 million. Losses were -$27.79 million, 18.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for EVGN stock is "Buy." The 12-month stock price forecast is 6.63, which is an increase of 772.60% from the latest price.

Price Target
$6.63
(772.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Canonic Launches its Second-Generation Medical Cannabis Products with High THC and Unique Terpene Profiles

The new and improved products are derived from novel proprietary cannabis varieties developed using genetic markers utilizing Evogene's GeneRator AI tech-engine REHOVOT, Israel , Sept. 21, 2022 /PRNewsw...

1 week ago - PRNewsWire

Lavie Bio Announces Appointment of Guri Oron as CEO

REHOVOT, Israel , Sept. 14, 2022 /PRNewswire/ -- Lavie Bio Ltd.

2 weeks ago - PRNewsWire

Canonic Advances its Penetration into Europe by Signing its First Licensing Agreement with GroVida

Portugal-based GroVida licenses two of Canonic's cannabis varieties for cultivation and commercialization in Europe REHOVOT, Israel , Sept. 13, 2022 /PRNewswire/ -- Canonic Ltd.

3 weeks ago - PRNewsWire

Evogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference

REHOVOT, Israel , Sept. 7, 2022 /PRNewswire/ -- Evogene Ltd.

3 weeks ago - PRNewsWire

Evogene (EVGN) Reports Q2 Loss, Tops Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of -16.67% and 83.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Evogene Reports Second Quarter 2022 Financial Results

Conference call and webcast: today, August 31, 2022, 9:00 am ET REHOVOT, Israel , Aug. 31, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targetin...

1 month ago - PRNewsWire

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

REHOVOT, Israel  , Aug. 25, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science prod...

1 month ago - PRNewsWire

ADDING MULTIMEDIA ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products

TEL AVIV, Israel--(BUSINESS WIRE)--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company focused...

Other symbols: ICL
1 month ago - Business Wire

ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products

TEL AVIV, Israel--(BUSINESS WIRE)--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company focused...

Other symbols: ICL
1 month ago - Business Wire

Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2022

REHOVOT, Israel , Aug. 2, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several m...

2 months ago - PRNewsWire

Biomica Appoints Professor Gal Markel to Company's Scientific Advisory Board

This addition to Biomica's scientific expertise will support the company's upcoming steps in its immuno-oncology clinical development program REHOVOT, Israel , July 28, 2022 /PRNewswire/ -- Biomica Ltd....

2 months ago - PRNewsWire

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug

REHOVOT, Israel , July 26, 2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

2 months ago - PRNewsWire

Biomica to Present at the Microbiome Connect Europe 2022

REHOVOT, Israel , July 5, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

2 months ago - PRNewsWire

Biomica to Present at the 7th Microbiome Movement Drug Development Summit

Dr. Elran Haber to participate in the Industry Leaders opening panel  at this premier Microbiome conference REHOVOT, Israel , June 15, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical co...

3 months ago - PRNewsWire

Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Evogene Reports First Quarter 2022 Financial Results

Conference call and webcast: today, May 26, 2022, 9:00 am ET REHOVOT, Israel , May 26, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to...

4 months ago - PRNewsWire

Biomica to Present at the ASCO 2022 Annual Meeting

REHOVOT, Israel , May 23, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

4 months ago - PRNewsWire

Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference

REHOVOT, Israel , May 16, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

4 months ago - PRNewsWire

Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result™ for the 2022 Spring Wheat Growing Season

Given wheat global shortages and high prices, Lavie foresees continued strong demand for its bio-inoculant result ™  and plans increased production for 2023 growing season REHOVOT, Israel , May 11, 2022...

Other symbols: CTVA
4 months ago - PRNewsWire

Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2022

REHOVOT, Israel , May 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several m...

4 months ago - PRNewsWire

Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research

The research will be focused on developing new treatments for Inflammatory Bowel Disease (IBD) REHOVOT, Israel, April 13, 2022 /PRNewswire/ -- Biomica Ltd. (Biomica), an emerging biopharmaceutical compa...

5 months ago - PRNewsWire

Evogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022

REHOVOT, Israel , March 14, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple...

6 months ago - PRNewsWire

Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of 10% and 107.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Evogene Reports Fourth Quarter and Full Year 2021 Financial Results

REHOVOT, Israel, March 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and developmen...

6 months ago - PRNewsWire

Evogene to Attend to World Agri-Tech Innovation Summit from March 22-23, 2022

REHOVOT, Israel, March 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple ...

6 months ago - PRNewsWire